Earlier today, Bionomics Limited (NASDAQ: BNOX) announced topline results from its Phase 2b ATTUNE trial of BNC210 for post-traumatic stress disorder (PTSD).
The trial met its primary endpoint of change in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity score from baseline to Week 12 (p=0.048).
HC Wainwright upgraded the stock from Neutral to Buy with a price target of $8.
With the SAD pivotal start garnering considerable attention, the management's priority shifts towards initiating discussions with the FDA in the latter half ...